Mats Wahlstrom Buys 60,000 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom purchased 60,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $2.53 per share, with a total value of $151,800.00. Following the completion of the transaction, the director directly owned 147,555 shares in the company, valued at $373,314.15. The trade was a 68.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TriSalus Life Sciences Trading Up 4.0%

NASDAQ TLSI opened at $3.15 on Wednesday. The firm has a market capitalization of $193.13 million, a P/E ratio of -2.23 and a beta of 0.56. The business has a fifty day simple moving average of $4.11 and a 200 day simple moving average of $5.10. TriSalus Life Sciences, Inc. has a 12 month low of $2.20 and a 12 month high of $7.95. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. On average, analysts predict that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Lake Street Capital lowered their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter valued at about $47,000. Invesco Ltd. bought a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at about $72,000. Abel Hall LLC bought a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at about $73,000. Finally, HighMark Wealth Management LLC bought a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at about $75,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.